- Home
- IVVD vs NBP Comparison
IVVD vs NBP Comparison
Compare IVVD & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVVD | NBP |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.9M | 225.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IVVD | NBP |
|---|---|---|
| Price | $0.61 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $8.75 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 5.2M | 770.0K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | N/A |
| Revenue Next Year | $41.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $1.46 |
| 52 Week High | $3.07 | $5.19 |
Technical Indicators
Market Signals| Indicator | IVVD | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 43.85 |
| Support Level | N/A | $1.67 |
| Resistance Level | $1.01 | $1.95 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.97 | 0.91 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.